Aurobindo Pharma

Market Cap

65,122.38 Cr

EPS

54.16

PE Ratio

18.72

Dividend Yield

0.40 %

Industry

Healthcare

52 Week High

1,592.00

52 Week low

984.30

PB Ratio

2.16

Debt to Equity

0.21

Sector

Pharmaceuticals

Investment Returns

In Long Term

In Short Term

1 Year

0.00%

2 Years

0.00%

3 Years

0.00%

4 Years

0.00%

5 Years

0.00%

Analyst Rating

- By Refinitiv from26 analysts

Analysts have suggested that investors can buy this stock

Buy76.92 %

76.92 %

Hold7.69 %

7.69 %

Sell15.38 %

15.38 %

Company News

View All News

US FDA Classifies Aurobindo Pharma's New Jersey Warehouse Inspection as 'OAI'Today

Aurobindo Pharma has reported that the US Food and Drug Administration (FDA) has classified the inspection of their New Jersey warehouse as 'Official Action Indicated' (OAI). This classification suggests that the FDA found significant issues during their inspection that require official action.

Aurobindo Pharma's Eugia Steriles Facility Completes FDA Pre-approval Inspection1 day ago

Aurobindo Pharma announced the completion of a US FDA pre-approval inspection at its Eugia Steriles facility. The inspection concluded with 5 procedural observations, indicating minor issues that need to be addressed.

Aurobindo Pharma Completes FDA Pre-Approval Inspection at Eugia Steriles2 days ago

Aurobindo Pharma has announced the completion of a US FDA pre-approval inspection at its Eugia Steriles facility. The inspection concluded with 5 procedural observations, indicating minor issues that need to be addressed.

Peer Comparison Compare Peers on Screener

Competitors	LTP	Market Cap (₹ Cr.)	P/E Ratio	Revenue (₹ Cr.)	YoY Revenue Growth %	Net Profit (₹ Cr.)	YoY Profit Growth %	RSI
Sun Pharmaceutical	1,669.30	4,00,520.99	34.13	49,887.20	12.06	9,648	13.77	37.74
Divis Laboratories	5,978.30	1,58,705.08	76.14	8,184.00	0.89	1,600	64.53	51.57
Cipla	1,479.70	1,19,502.65	23.70	26,520.70	14.17	4,155	47.38	51.15
Torrent Pharmaceuticals	3,095.95	1,04,781.02	56.64	10,785.70	11.59	1,656	13.54	45.77
Dr Reddys Laboratories	1,170.95	97,705.34	18.09	28,905.40	12.36	5,578	1.69	30.83
Mankind Pharma	2,348.45	96,889.27	47.77	10,615.60	19.57	1,942	-16.38	39.42
Zydus Life Science	899.65	90,525.84	19.78	19,831.50	13.82	3,831	29.92	36.77
Lupin	1,977.50	90,213.07	31.46	20,141.50	19.94	1,936	38.82	38.83
Aurobindo Pharma	1,121.25	65,122.38	18.72	29,559.20	17.55	3,169	-10.04	42.81
Abbott	29,429.65	62,535.95	47.37	6,097.20	10.80	1,201	16.01	61.56

Growth Rate

Revenue Growth

17.55 %

Net Income Growth

64.39 %

Cash Flow Change

2.00 %

ROE

47.91 %

ROCE

46.65 %

EBITDA Margin (Avg.)

35.82 %

Quarterly Financial Results

Quarterly Financials	Mar 2015	Jun 2015	Sept 2015	Dec 2015	Mar 2016	Jun 2016	Sept 2016	Dec 2016	Mar 2017	Jun 2017	Sept 2017	Dec 2017	Mar 2018	Jun 2018	Sept 2018	Dec 2018	Mar 2019	Jun 2019	Sept 2019	Dec 2019	Mar 2020	Jun 2020	Sept 2020	Dec 2020	Mar 2021	Jun 2021	Sept 2021	Dec 2021	Mar 2022	Jun 2022	Sept 2022	Dec 2022	Mar 2023	Jun 2023	Sept 2023	Dec 2023	Mar 2024	Jun 2024	Sept 2024	Dec 2024
Revenue	3,151	3,272	3,324	3,450	3,710	3,728	3,742	3,871	3,625	3,645	4,366	4,302	4,033	4,226	4,694	5,242	5,234	5,377	5,539	5,830	6,108	5,951	6,432	9,300	6,071	5,802	5,987	6,089	5,844	6,218	5,731	6,481	6,514	6,907	7,339	7,434	7,628	7,679	7,783	8,052
Expenses	2,506	2,574	2,586	2,688	2,885	2,878	2,847	3,011	2,920	2,845	3,319	3,311	3,261	3,539	3,792	4,208	4,271	4,311	4,473	4,701	4,862	4,679	5,071	5,011	4,735	4,502	4,766	4,993	5,002	5,303	4,950	5,453	5,477	5,772	5,846	5,753	6,042	5,949	6,230	6,401
EBITDA	645	698	738	762	825	851	895	860	704	800	1,047	992	772	687	902	1,033	963	1,066	1,066	1,130	1,247	1,271	1,361	4,290	1,335	1,300	1,220	1,096	842	914	781	1,027	1,037	1,135	1,493	1,681	1,585	1,730	1,553	1,652
Operating Profit %	20 %	21 %	22 %	22 %	21 %	22 %	23 %	22 %	18 %	21 %	24 %	22 %	18 %	15 %	19 %	19 %	18 %	20 %	19 %	19 %	20 %	20 %	20 %	21 %	21 %	21 %	19 %	17 %	14 %	14 %	13 %	15 %	14 %	15 %	18 %	21 %	19 %	20 %	19 %	19 %
Depreciation	85	89	93	99	111	106	110	111	100	131	132	138	157	155	164	163	187	241	243	250	232	256	257	277	266	280	294	299	254	280	298	321	346	327	418	423	354	404	382	419
Interest	21	31	68	9	25	21	18	14	14	17	17	19	25	30	35	48	50	50	41	37	32	21	16	20	18	13	10	16	9	15	25	45	56	57	68	76	89	111	113	119
Profit Before Tax	557	634	631	717	761	786	830	796	649	709	979	902	651	571	787	917	816	863	864	938	1,078	1,084	1,193	4,005	1,061	1,018	968	794	594	679	523	680	730	812	1,076	1,262	1,230	1,324	1,208	1,200
Tax	153	162	178	173	206	201	224	218	117	191	198	307	122	116	175	205	231	228	224	233	229	301	386	1,058	260	248	271	190	18	159	113	189	224	242	324	323	323	406	391	354
Net Profit	403	472	453	545	555	585	606	579	532	518	781	595	529	456	611	712	585	636	640	705	849	783	807	2,948	801	770	697	604	576	520	410	491	506	570	752	940	907	918	817	846
EPS in ₹	13.84	16.18	7.77	9.32	9.49	9.99	10.41	9.88	9.10	8.85	13.33	10.16	9.02	7.78	10.44	12.15	9.99	10.85	10.92	12.04	14.50	13.32	13.78	50.31	13.67	13.14	11.89	10.32	9.84	8.88	6.99	8.38	8.64	9.74	12.83	16.04	15.51	15.69	14.00	14.56

Show % Change

Above figures are in Rs. Crores

Balance Sheet

Balance Sheet	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	12,915	15,920	16,249	21,101	26,454	28,928	33,854	33,922	39,890	45,072
Fixed Assets	3,706	4,180	4,834	6,521	8,475	9,397	9,374	10,532	11,024	14,493
Current Assets	8,299	10,294	9,206	12,178	15,332	16,413	19,824	18,123	21,460	23,772
Capital Work in Progress	420	848	1,458	1,583	1,669	1,986	3,062	3,747	5,390	3,869
Investments	20	123	246	312	360	555	591	997	543	372
Other Assets	8,770	10,769	9,712	12,686	15,951	16,991	20,828	18,645	22,934	26,338
Total Liabilities	12,915	15,920	16,249	21,101	26,454	28,928	33,854	33,922	39,890	45,072
Current Liabilities	6,136	7,840	6,606	8,666	12,021	11,385	10,665	8,156	11,494	12,199
Non Current Liabilities	1,596	790	270	753	541	718	1,260	1,192	1,544	3,022
Total Equity	5,182	7,290	9,374	11,682	13,892	16,825	21,929	24,574	26,852	29,851
Reserve & Surplus	5,127	7,229	9,313	11,622	13,832	16,766	21,871	24,517	26,781	29,784
Share Capital	29	59	59	59	59	59	59	59	59	59

Show % Change

Above figures are in Rs. Crores

Cash Flow

Cash Flow	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Cash Flow	313	340	-424	892	666	871	2,561	-1,164	230	-1,007
Investing Activities	-1,017	-1,446	-1,787	-1,927	-2,904	-1,563	597	-3,211	-3,971	-4,242
Operating Activities	1,237	1,420	3,279	1,955	1,651	4,381	3,329	5,017	2,387	2,435
Financing Activities	93	365	-1,915	864	1,919	-1,947	-1,365	-2,969	1,814	800

Show % Change

Above figures are in Rs. Crores

Share Holding

% Holding	Mar 2021	Jun 2021	Sept 2021	Dec 2021	Mar 2022	Jun 2022	Sept 2022	Dec 2022	Mar 2023	Jun 2023	Sept 2023	Dec 2023	Mar 2024	Jun 2024	Sept 2024	Dec 2024
Promoter	51.94 %	51.83 %	51.83 %	51.83 %	51.83 %	51.83 %	51.83 %	51.83 %	51.83 %	51.83 %	51.83 %	51.83 %	51.83 %	51.80 %	51.82 %	51.82 %
FIIs	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.01 %	0.00 %	0.00 %	0.00 %	0.00 %	18.02 %	16.73 %	16.59 %	16.29 %
DIIs	10.99 %	12.72 %	13.82 %	15.11 %	15.83 %	15.58 %	16.23 %	14.89 %	15.08 %	15.73 %	17.94 %	20.23 %	23.28 %	24.77 %	25.13 %	25.20 %
Government	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %
Public / Retail	8.71 %	8.54 %	9.60 %	8.99 %	8.37 %	8.80 %	8.65 %	9.42 %	8.54 %	7.01 %	6.15 %	5.64 %	5.52 %	5.47 %	5.33 %	5.52 %
Others	28.36 %	26.91 %	24.74 %	24.07 %	23.97 %	23.79 %	23.29 %	23.85 %	24.54 %	25.42 %	24.07 %	22.29 %	1.36 %	1.23 %	1.13 %	1.17 %
No of Share Holders	2,32,634	2,43,315	3,29,940	3,41,568	3,38,639	3,59,684	3,58,459	3,69,828	3,43,617	2,93,214	2,59,638	2,41,944	2,44,575	2,38,622	2,48,488	2,57,962